U.S. Patent No. 10,477,791 B2 (‘791) issued on November 19, 2019, entitled ”Method of Production of Phytocannabinoids for Use in Medical Treatments.” It was issued to inventor Peter Andrew Whitton of Leicester, Great Britain. The applicant/assignee is Cell Science Holding Ltd. of Limassol, Cyprus.
The specification discloses a new process for producing phytocannabinoids, or the naturally occurring cannabinoids found within the Cannabis plant (as opposed to the synthetic cannabinoids). Because cannabis is grown using conventional agricultural methods, cannabinoid content will vary according to plant, which creates content inconsistency. Further, hydroponic systems require large quantities of water for growing cannabis. The claimed invention eliminates issues related to these two conventional methods, by synthetically growing cannabinoid content-controlled tissue culture. The ‘791 claims are directed to the method of producing the cannabinoid comprising the steps of tissue selection and growth through cell suspension and control of light exposure during suspension, then extraction of the cannabinoids from the cell suspension culture.
There were no drawings submitted with the application.
The Cooperative Patent Classification is A01H, new plants or processes for obtaining them, namely, plant reproduction by tissue culture techniques by methods for micropropagation (4/005); A61K, preparations for medical, dental, or toilet purposes, namely, medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, namely, magnoliopsida (36/185); and C12N, microorganisms or enzymes, namely, plant cells or tissues (5/04).
Cannabis patents still represent a huge growth area for patent procurement and development, as the legalized industry is still in its infancy throughout much of the country. Please contact Yonaxis for more information or if you have any questions.